Emmaus Life Sciences Competitors

Emmaus Life Sciences (OTCMKTS:EMMA) and Caladrius Biosciences (NASDAQ:CLBS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Analyst Ratings

This is a summary of current ratings and target prices for Emmaus Life Sciences and Caladrius Biosciences, as reported by MarketBeat.com.

Caladrius Biosciences has a consensus price target of $10.00, indicating a potential upside of 553.59%. Given Caladrius Biosciences' higher probable upside, analysts plainly believe Caladrius Biosciences is more favorable than Emmaus Life Sciences.

Earnings & Valuation

This table compares Emmaus Life Sciences and Caladrius Biosciences' gross revenue, earnings per share (EPS) and valuation.

Emmaus Life Sciences has higher revenue and earnings than Caladrius Biosciences.

Insider and Institutional Ownership

0.1% of Emmaus Life Sciences shares are held by institutional investors. Comparatively, 9.0% of Caladrius Biosciences shares are held by institutional investors. 36.9% of Emmaus Life Sciences shares are held by company insiders. Comparatively, 10.3% of Caladrius Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Emmaus Life Sciences and Caladrius Biosciences' net margins, return on equity and return on assets.

Volatility & Risk

Emmaus Life Sciences has a beta of 2.34, indicating that its stock price is 134% more volatile than the S&P 500. Comparatively, Caladrius Biosciences has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500.

Summary

Emmaus Life Sciences beats Caladrius Biosciences on 6 of the 9 factors compared between the two stocks.

Emmaus Life Sciences (OTCMKTS:EMMA) and Baudax Bio (NASDAQ:BXRX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

Profitability

This table compares Emmaus Life Sciences and Baudax Bio's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Emmaus Life Sciences and Baudax Bio's revenue, earnings per share (EPS) and valuation.

Emmaus Life Sciences has higher revenue and earnings than Baudax Bio.

Analyst Recommendations

This is a summary of current ratings for Emmaus Life Sciences and Baudax Bio, as reported by MarketBeat.com.

Baudax Bio has a consensus target price of $13.50, suggesting a potential upside of 1,161.68%. Given Baudax Bio's higher possible upside, analysts clearly believe Baudax Bio is more favorable than Emmaus Life Sciences.

Insider & Institutional Ownership

0.1% of Emmaus Life Sciences shares are held by institutional investors. Comparatively, 7.9% of Baudax Bio shares are held by institutional investors. 36.9% of Emmaus Life Sciences shares are held by company insiders. Comparatively, 13.1% of Baudax Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Volatility & Risk

Emmaus Life Sciences has a beta of 2.34, indicating that its stock price is 134% more volatile than the S&P 500. Comparatively, Baudax Bio has a beta of 2.56, indicating that its stock price is 156% more volatile than the S&P 500.

Summary

Baudax Bio beats Emmaus Life Sciences on 4 of the 7 factors compared between the two stocks.

Emmaus Life Sciences (OTCMKTS:EMMA) and Cryo-Cell International (OTCMKTS:CCEL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations.

Volatility & Risk

Emmaus Life Sciences has a beta of 2.34, suggesting that its share price is 134% more volatile than the S&P 500. Comparatively, Cryo-Cell International has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500.

Profitability

This table compares Emmaus Life Sciences and Cryo-Cell International's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Emmaus Life Sciences and Cryo-Cell International's top-line revenue, earnings per share (EPS) and valuation.

Cryo-Cell International has higher revenue and earnings than Emmaus Life Sciences.

Analyst Recommendations

This is a summary of current recommendations for Emmaus Life Sciences and Cryo-Cell International, as provided by MarketBeat.

Insider and Institutional Ownership

0.1% of Emmaus Life Sciences shares are held by institutional investors. Comparatively, 1.0% of Cryo-Cell International shares are held by institutional investors. 36.9% of Emmaus Life Sciences shares are held by insiders. Comparatively, 53.8% of Cryo-Cell International shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Cryo-Cell International beats Emmaus Life Sciences on 6 of the 9 factors compared between the two stocks.

GreenVision Acquisition (NASDAQ:GRNV) and Emmaus Life Sciences (OTCMKTS:EMMA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, profitability, risk and analyst recommendations.

Analyst Recommendations

This is a summary of recent recommendations and price targets for GreenVision Acquisition and Emmaus Life Sciences, as reported by MarketBeat.com.

Valuation & Earnings

This table compares GreenVision Acquisition and Emmaus Life Sciences' revenue, earnings per share and valuation.

GreenVision Acquisition has higher earnings, but lower revenue than Emmaus Life Sciences.

Insider & Institutional Ownership

67.7% of GreenVision Acquisition shares are held by institutional investors. Comparatively, 0.1% of Emmaus Life Sciences shares are held by institutional investors. 36.9% of Emmaus Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares GreenVision Acquisition and Emmaus Life Sciences' net margins, return on equity and return on assets.

Summary

Emmaus Life Sciences beats GreenVision Acquisition on 2 of the 3 factors compared between the two stocks.

Pacific Health Care Organization (OTCMKTS:PFHOD) and Emmaus Life Sciences (OTCMKTS:EMMA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.

Insider & Institutional Ownership

0.1% of Emmaus Life Sciences shares are owned by institutional investors. 61.6% of Pacific Health Care Organization shares are owned by company insiders. Comparatively, 36.9% of Emmaus Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Pacific Health Care Organization has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, Emmaus Life Sciences has a beta of 2.34, suggesting that its share price is 134% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Pacific Health Care Organization and Emmaus Life Sciences, as reported by MarketBeat.com.

Profitability

This table compares Pacific Health Care Organization and Emmaus Life Sciences' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Pacific Health Care Organization and Emmaus Life Sciences' gross revenue, earnings per share and valuation.

Pacific Health Care Organization has higher revenue and earnings than Emmaus Life Sciences.

Summary

Pacific Health Care Organization beats Emmaus Life Sciences on 6 of the 9 factors compared between the two stocks.

Emmaus Life Sciences (OTCMKTS:EMMA) and Curative Biotechnology (OTCMKTS:CTYX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Profitability

This table compares Emmaus Life Sciences and Curative Biotechnology's net margins, return on equity and return on assets.

Volatility & Risk

Emmaus Life Sciences has a beta of 2.34, indicating that its share price is 134% more volatile than the S&P 500. Comparatively, Curative Biotechnology has a beta of -31.94, indicating that its share price is 3,294% less volatile than the S&P 500.

Institutional and Insider Ownership

0.1% of Emmaus Life Sciences shares are owned by institutional investors. 36.9% of Emmaus Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Emmaus Life Sciences and Curative Biotechnology, as reported by MarketBeat.

Valuation and Earnings

This table compares Emmaus Life Sciences and Curative Biotechnology's top-line revenue, earnings per share (EPS) and valuation.

Curative Biotechnology has lower revenue, but higher earnings than Emmaus Life Sciences.

Summary

Emmaus Life Sciences beats Curative Biotechnology on 4 of the 4 factors compared between the two stocks.